NG 2001
Alternative Names: NG-2001Latest Information Update: 15 Sep 2021
At a glance
- Originator NanoGhost
- Class Antineoplastics; Interleukins; MicroRNAs
- Mechanism of Action Interleukin-2 replacements; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 30 Aug 2021 Preclinical trials in Solid tumours in Israel (unspecified route) before August 2021 (NanoGhost pipeline, August 2021)